equityflowunderstand the flow and follow it
EquityFlow › Companies › Bionyra Pharma

Bionyra Pharma

biotech · Paris, FR

A clinical-stage biopharma developing next-generation biologics for immune-mediated inflammatory diseases.

Funding history

DateRoundAmount
Jun 2026Series A
Bionyra Pharma launched with an oversubscribed 143 million euro Series A to advance its pipeline of antibodies for inflammatory diseases such as atopic dermatitis and IBD.
$165M

Investors

Tap an investor to see what else they have backed.

Apollo Health VenturesArkin BioJeito CapitalSanofi VenturesSixty Degree CapitalSofinnova PartnersVIVES Partners

Other companies in biotech

Antag TherapeuticsAdcendoFreya BiosciencesTXN SystemsPromise BioConcinnity GeneticsNoema PharmaMabGenesisRadioNano TherapeuticsCitryllAlveron PharmaAQEMIA

Other companies in FR

CardNexusMendoUncovrAlta AresInnovafeedInnovorderQuoblyMokNWandercraftArlequin AIKoletFungu'it

Other companies at Series A stage

&Done&Open011h01Health1000 Satellites100ms11x.ai12 Pharmacy180° Seguros1X Technologies1k Kirana Bazaar207
Explore funding flow on EquityFlow →

Data is community-curated and may be incomplete.